The 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) was successfully held from January 8–10, 2026, in San Francisco, California, with both in-person and online participation, making it accessible to the global gastrointestinal oncology community. The event served as a crucial platform for medical oncologists, surgeons, radiation oncologists, researchers, and patient advocates to converge and discuss the latest breakthroughs in GI cancer prevention, diagnosis, and treatment. The symposium highlighted cutting-edge research, clinical best practices, and novel innovations across various GI cancer types. Dr. Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, played an active role, sharing key highlights and observations from the ongoing sessions. His reported highlights included results in resectable and advanced gastric cancer from trials like NEOSUMMIT-01, CRITICS II, ILUSTRO, and HORIZON-GEA-1. The targeting of Claudin 18.2 (Zolbetuximab) and Her2 (Zanidatamab) in the advanced setting was particularly emphasized. Dr. El-Deiry also noted presentations on strategies to avoid esophagectomy in locally advanced esophageal cancer. Other significant topics included early-onset GI cancers, the role of AI in GI oncology, and new guidance on DPYD variant testing before fluoropyrimidine treatment to reduce toxicities. The symposium fostered knowledge-sharing and collaboration, presenting research that could potentially be practice-changing in the field of GI oncology.